Ruti Aga's Six-Year Ban: Methylprednisolone, a Forged Prescription, and the Paperwork That Outgrew a Marathon Career

A clinic in Ethiopia received one question from the Athletics Integrity Unit: is this prescription yours? The answer was no. The person who wrote it held no medical registration. That person's own explanation was that he had used an old prescription pad from a former workplace — a pad the former workplace explicitly disowned.

Ruti Aga is 32. She won the 2026 Tokyo Marathon. She has finished second at World Marathon Majors three times. In March she won a half marathon in China, and the in-competition sample from that race returned methylprednisolone. The AIU's statement imposes six years: two for the presence violation, four for tampering. The ban is dated from 10 September, the day her provisional suspension began.

I keep returning to the lanyard, because access is never just a credential.

In marathon running the document that matters is never the medal certificate. It is the team physician's registration, the clinic record, the entry logging an injection's date and dose, and the therapeutic use exemption file that explains why a banned substance entered the body and by which route. Aga had none of that. She had a pad.

I watched the 2026 Tokyo Marathon at about 5:40 a.m. IST, before a shift, on a stream that stalled twice. Aga won it in 2:20:40. Public records list her Berlin 2026 second place at roughly 2:18:34. That is a 2:18–2:20 athlete, and in Ethiopia that does not guarantee selection. The women's marathon cohort that matters there sits under 2:16; the world record sits in the same country. Removing one 2:18 runner moves nothing in the national team's arithmetic.

Now the part the statement does not contain, which in reporting is often where the story lives. There is no time for the Chinese half marathon, no field depth, not even the year, and — most telling — no stated scope of disqualification. When a release omits that much, the reader should assume the text is complete and the silence is not.

One thing is certain: the race was won. A win on the road implies a World Athletics Label-tier elite field and in-competition testing. Without testing, this case would not exist. A road race's testing window opens at 23:59 the night before. That administrative detail is the spine of the case, and most coverage has missed it.

Because the question is not what methylprednisolone is. It is what class it belongs to.

Methylprednisolone is a glucocorticoid — class S9 on the WADA Prohibited List — not an anabolic steroid, which is S1. Under S9, it is prohibited in-competition only, and only by injection, oral or rectal route. A therapeutic knee injection given out of competition is entirely legal. It becomes a violation only when residues are present in-competition.

The entire legal hinge of this case sat on route and timing, not on the drug — which is exactly where a defence existed.

Intra-articular or peri-articular methylprednisolone for knee synovitis is ordinary sports-medicine practice in distance runners, for whom chronic knee pathology is a known failure mode at 180–200 kilometres a week. The knee-injury explanation is medically credible. Credibility is not a defence. A defence is a document.

And in place of a document there was a prescription.

The six-year arithmetic is plain addition: two years for presence, four for tampering — and the addition itself tells us the panel rejected the no-significant-fault mitigation.

The two-year figure signals a Specified Substance finding without proven intent, which carries a two-year base. The four-year figure is the Code's standard tampering sanction for fabricated documents or misleading statements. Six is not anomalous. What is anomalous is that the tampering charge arose from an interview, not from a document alone — a detail that matters, given the recurring contention about language and translation conditions in AIU interviews with Ethiopian athletes.

Backdating to 10 September is procedural housekeeping, not a discount. Provisional suspension time counts against the ban; nothing is gained. The real cost is calendar: six years removes the 2028 Los Angeles cycle entirely, and a ban starting at 32 ends near 38, an age at which Ethiopian selection with a doping record is implausible.

This case began with a substance and ended with paperwork, and that is the actual news.

A counterfactual existed, and it was not distant. A registered team physician, a clinic record, a logged injection date and route, a proper washout period — best case, no case at all. Intermediate case: genuine records plus a route-and-timing explanation argued at the no-fault end, potentially a reprimand or a substantially reduced period, with no tampering charge. What happened was the third path.

They called the column brave; I thought it was just the truth arriving late.

I do not read this as a story about one athlete's ethics. I read it as a story about the structure elite East African road running operates inside. A marathoner's income is appearance fees, not prize money. For a 2:18–2:20 runner the efficient model is two or three Majors a year with Asian label races between them, where start money is good and the field is manageable. Aga's pattern fits that model.

The model has a fracture. When income depends on starting and the knee speaks, the cheapest available tool is a glucocorticoid: suppress the inflammation, race, collect. When no legitimate file exists for that treatment, the next step is manufacturing one. The prescription is a symptom of an untreated governance gap.

Two economies now collide in the same race: the appearance-fee economy and the testing economy. China's label circuit concentrates large start budgets, deep East African fields and AIU testing on the same morning, which means results from that tier will increasingly carry integrity risk.

Here is where I part with much of the coverage. Several reports called methylprednisolone a prohibited steroid and said WADA classes it as performance enhancing. That is imprecise, and the error reframes the case. Methylprednisolone is an anti-inflammatory glucocorticoid with no established endurance benefit. A six-year ban for a drug that does not make anyone faster is not a story about speed. It is a story about documents.

And if it is a story about documents, the question becomes where the enforcement frontier now sits — detection, or verification?

The cold answer is that it has moved. The pattern across recent East African road-running cases is a substance violation compounded by an explanation. An athlete with a registered physician, TUE literacy and a filing habit takes the correct path at the first violation. An athlete without that infrastructure reaches the second. The sanction measures the gap, not the degree of cheating.

One clarification, because this case will be used from both directions. It will be cited as proof of AIU rigour, and as proof of disproportionate enforcement against African road runners. The second argument weakens once the arithmetic is read: most of the penalty is for fabricated paperwork, not the substance. The first two years are the least contested part of this file.

A CAS appeal is live, typically within about 21 days of the reasoned decision, but the forgery finding rests on documents — a clinic that disowned the prescription, an absent registration, a pad story offered by the defence itself. Reversing that needs new facts, not new argument.

And what the statement omits, standard AIU practice supplies: the March result and its prize money should be void, along with ranking points accrued after that date. Earlier results are not automatically annulled. The 2026 Tokyo title survives absent evidence of earlier use, as do three Major runner-up finishes.

Six weeks of silence, then one microphone.

I wrote that line for myself in 2026, when the calendar vanished. What I learned then applies directly here: absence is material. What is missing from a broadcast — the crowd, the budget, the second voice — is often the largest part of the story. What is missing from the AIU release — the time, the disqualification scope, the year — tells you this was never about performance.

The camp structure I witnessed as a child in Kenya was thin: a few coaches, a few training partners, a trainer who taped a knee and sent you out the next morning. I will not pronounce on East African sports medicine as though birthplace were expertise; I will cite what I saw, and quote those who reported what I did not. What I saw is that the distance between a clinic and a camp is never recorded on paper. It becomes visible only when an investigator asks, and by then it is late.

What survives this case, beyond a career ending?

A clear signal, and a less moral one than it appears. In the coming years the fastest-moving part of anti-doping in road running will not be the laboratory. It will be the filing cabinet: TUE literacy, physician registration, injection logs, and the verification of all three. Those who have that scaffolding will survive a first violation. Those who do not will fall at the second.

The question is not what Ruti Aga did. It is why a 32-year-old distance runner had no real document for the treatment of her own knee, when someone else in the same race did. The likely answer is that the lanyard required for that document is not handed out evenly.